{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T21:27:51Z","timestamp":1788470871805,"version":"build-2803163510"},"reference-count":29,"publisher":"Japanese Society of Toxicologic Pathology","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Toxicol Pathol"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1293\/tox.2024-0037","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T22:11:06Z","timestamp":1732054266000},"page":"93-111","source":"Crossref","is-referenced-by-count":1,"title":["Histopathology of incidental non-neoplastic findings in transgenic CByB6F1-Tg(HRAS)2Jic mice used in toxicity studies"],"prefix":"10.1293","volume":"38","author":[{"given":"Marcia E","family":"Pereira Bacares","sequence":"first","affiliation":[{"name":"Labcorp Early Development Laboratories, Inc., 3635 Concorde Parkway, Suite 100, Chantilly, VA, 20151, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward L","family":"Stevens","sequence":"additional","affiliation":[{"name":"Labcorp Early Development Laboratories, Inc., 3635 Concorde Parkway, Suite 100, Chantilly, VA, 20151, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Laast","sequence":"additional","affiliation":[{"name":"Labcorp Early Development Laboratories, Inc., 3635 Concorde Parkway, Suite 100, Chantilly, VA, 20151, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vimala","family":"Vemiredi","sequence":"additional","affiliation":[{"name":"Labcorp Early Development Laboratories, Inc., 3635 Concorde Parkway, Suite 100, Chantilly, VA, 20151, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hibret A","family":"Adissu","sequence":"additional","affiliation":[{"name":"Labcorp Early Development Laboratories, Inc., 3635 Concorde Parkway, Suite 100, Chantilly, VA, 20151, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G","family":"Mense","sequence":"additional","affiliation":[{"name":"Labcorp Early Development Laboratories, Inc., 3635 Concorde Parkway, Suite 100, Chantilly, VA, 20151, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"121","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1.  MacDonald J, French JE, Gerson RJ, Goodman J, Inoue T, Jacobs A, Kasper P, Keller D, Lavin A, Long G, McCullough B, Sistare FD, Storer R, van der Laan JW. The Alternatives to Carcinogenicity Testing Committee ILSI HESI. The utility of genetically modified mouse assays for identifying human carcinogens: a basic understanding and path forward. Toxicol Sci. 77: 188\u2013194. 2004.","DOI":"10.1093\/toxsci\/kfh037"},{"key":"2","unstructured":"2.  Hickam S. Initial development of transgenic mouse models for carcinogenicity testing and review of the regulatory environment. Am Lab. 47: 14\u201317. 2015."},{"key":"3","first-page":"1195","volume":"5","year":"1990","unstructured":"3.  Saitoh A, Kimura M, Takahashi R, Yokoyama M, Nomura T, Izawa M, Sekiya T, Nishimura S, and Katsuki M. Most tumors in transgenic mice with human c-Ha-ras gene contained somatically activated transgenes. Oncogene. 5: 1195\u20131200. 1990.","journal-title":"Oncogene","ISSN":"https:\/\/id.crossref.org\/issn\/0950-9232","issn-type":"print"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4.  Morton D, Alden CL, Roth AJ, and Usui T. The Tg rasH2 mouse in cancer hazard identification. Toxicol Pathol. 30: 139\u2013146. 2002.","DOI":"10.1080\/01926230252824851"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5.  Bogdanffy MS, Lesniak J, Mangipudy R, Sistare FD, Colman K, Garcia-Tapia D, Monticello T, and Blanset D. Tg.rasH2 mouse model for assessing carcinogenic potential of pharmaceuticals: industry survey of current practices. Int J Toxicol. 39: 198\u2013206. 2020.","DOI":"10.1177\/1091581820919896"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6.  Mitsumori K, Koizumi H, Nomura T, and Yamamoto S. Pathological features of spontaneous and induced tumors in transgenic mice carrying a human prototype c-Ha-ras gene used for six-month carcinogenicity studies. Toxicol Pathol. 26: 520\u2013531. 1998.","DOI":"10.1177\/019262339802600408"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7.  Kanno H, Tanakamura Z, Ishimura Y, Kandori H, Yamasaki H, and Sasaki S. Historical background data in CB6F1-Tg-rasH2 mice and CB6F1-nonTg-rasH2 mice over a 26-week experimental period. J Toxicol Pathol. 16: 267\u2013274. 2003.","DOI":"10.1293\/tox.16.267"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8.  Long GG, Goodman DG, Credille KM, Mann PC, Wilson JM, and Cardy R. Hematopoietic proliferative lesions in the spleen of rasH2 transgenic mice treated with MNU. Toxicol Pathol. 38: 1026\u20131036. 2010.","DOI":"10.1177\/0192623310382557"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9.  Nambiar PR, Turnquist SE, and Morton D. Spontaneous tumor incidence in rasH2 mice: review of internal data and published literature. Toxicol Pathol. 40: 614\u2013623. 2012.","DOI":"10.1177\/0192623311436181"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10.  Paranjpe MG, Elbekaei RH, Shah SA, Hickman M, Wenk ML, and Zahalka EA. Historical control data of spontaneous tumors in transgenic CByB6F1-Tg(HRAS)2Jic (Tg.rasH2) mice. Int J Toxicol. 32: 48\u201357. 2013.","DOI":"10.1177\/1091581812471565"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11.  Paranjpe MG, Denton MD, and Elbekai RH. The 26-week Tg.rasH2 mice carcinogenicity studies: microscopic examination of only select tissues in low- and mid-dose groups. Toxicol Pathol. 42: 1153\u20131157. 2014.","DOI":"10.1177\/0192623313501726"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12.  Paranjpe MG, Belich JL, McKeon ME, Elbekai RH, Mann PC, Hard GC, and Seely JC. Renal tumors in 26-week Tg.rasH2 mice carcinogenicity studies. Toxicol Pathol. 44: 633\u2013635. 2016.","DOI":"10.1177\/0192623315627216"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13.  Paranjpe MG, Belich JL, Richardson DR, Vidmar T, Mann PC, McKeon ME, and Elbekai RH. Progression of serosal vascular proliferative lesions to hemangiosarcomas in the uterus of the 26-Week Tg.rasH2 mice carcinogenicity studies. Int J Toxicol. 36: 29\u201334. 2017.","DOI":"10.1177\/1091581816659068"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14.  Paranjpe MG, Belich JL, Mann PC, McKeon ME, Elbekai RH, Brown CM, and Patrick DJ. A comparison of spontaneous tumors in Tg.rasH2 Mice in 26-week carcinogenicity studies conducted at a single test facility during 2004 to 2012 and 2013 to 2018. Toxicol Pathol. 47: 18\u201325. 2019.","DOI":"10.1177\/0192623318810202"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15.  Takaoka M, Sehata S, Maejima T, Imai T, Torii M, Satoh H, Toyosawa K, Tanakamaru ZY, Adachi T, Hisada S, Ueda M, Ogasawara H, Matsumoto M, Kobayashi K, Mutai M, and Usui T. Interlaboratory comparison of short-term carcinogenicity studies using CB6F1-rasH2 transgenic mice. Toxicol Pathol. 31: 191\u2013199. 2003.","DOI":"10.1080\/01926230390183670"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16.  Paranjpe MG, Shah SA, Denton MD, and Elbekai RH. Incidence of spontaneous non-neoplastic lesions in transgenic CBYB6F1-Tg(HRAS)2Jic mice. Toxicol Pathol. 41: 1137\u20131145. 2013.","DOI":"10.1177\/0192623313478207"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17.  Boyle MH, Paranjpe MG, and Creasy DM. High background incidence of spontaneous subcapsular adrenal gland hyperplasia of Tg.rasH2 mice used in 26-week carcinogenicity studies. Toxicol Pathol. 46: 444\u2013448. 2018.","DOI":"10.1177\/0192623318770965"},{"key":"18","unstructured":"18.  De Jonghe S, Verbeeck J, Van Deun K, Brown M, Vynckier A, Vandenberghe J, Verstynen B, Lampo A, Monbaliu J, Jansen T, and Coussenent W. Results of 6 month oral carcinogenicity study with 17 beta-estradiol in transgenic TgHrasH2 and wild type mice. In: Workshop on the Evaluation of Alternative Methods for Carcinogenicity Testing. International Life Sciences Institute, Washington DC. 2000."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19.  Tsuchiya T, Kobayashi K, Sakairi T, Goto K, Okada M, Sano F, Sugimoto J, Morohashi T, Usui T, and Mutai M. Skeletal myopathy in transgenic mice carrying human prototype c-Ha-ras gene. Toxicol Pathol. 30: 501\u2013506. 2002.","DOI":"10.1080\/01926230290105677"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20.  Tamaoki N. The rasH2 transgenic mouse: nature of the model and mechanistic studies on tumorigenesis. Toxicol Pathol. 29(Suppl): 81\u201389. 2001.","DOI":"10.1080\/019262301753178492"},{"key":"21","unstructured":"21.  Frith CH, Highman B, Burger G, and Sheldon WD. Spontaneous lesions in virgin and retired breeder BALB\/c and C57BL\/6 mice. Lab Anim Sci. 33: 273\u2013286. 1983."},{"key":"22","unstructured":"22.  Frith CH, Ward JM. Color Atlas of Neoplastic and Non-neoplastic Lesions in Aging Mice. CL Davis DVM foundation, Gurnee. 1988."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23.  Pettan-Brewer C, and Treuting PM. Practical pathology of aging mice. Pathobiol Aging Age Relat Dis. 1: 7202. 2011.","DOI":"10.3402\/pba.v1i0.7202"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24.  Cora MC, Kooistra L, and Travlos G. Vaginal cytology of the laboratory rat and mouse: review and criteria for the staging of the estrous cycle using stained vaginal smears. Toxicol Pathol. 43: 776\u2013793. 2015.","DOI":"10.1177\/0192623315570339"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25.  Cooper TK, Meyerholz DK, Beck AP, Delaney MA, Piersigilli A, Southard TL, and Brayton CF. Research-relevant conditions and pathology of laboratory mice, rats, gerbils, guinea pigs, hamsters, nake mode rats, and rabbits. ILAR J. 62: 77\u2013132. 2021.","DOI":"10.1093\/ilar\/ilab022"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26.  Pearse G. Histopathology of the thymus. Toxicol Pathol. 34: 515\u2013547. 2006.","DOI":"10.1080\/01926230600978458"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27.  Doi T, Kotani Y, Kokoshima H, Kanno T, Wako Y, and Tsuchitani M. Eosinophilic substance is \u201cnot amyloid\u201d in the mouse nasal septum. Vet Pathol. 44: 796\u2013802. 2007.","DOI":"10.1354\/vp.44-6-796"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28.  Monticello TM, Morgan KT, and Uraih L. Nonneoplastic nasal lesions in rats and mice. Environ Health Perspect. 85: 249\u2013274. 1990.","DOI":"10.1289\/ehp.85-1568333"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29.  Chamanza R, and Wright JA. A review of the comparative anatomy, histology, physiology and pathology of the nasal cavity in rats, mice, dogs and non-human primates. Relevance to inhalation toxicity and human health risk assessment. J Comp Pathol. 153: 287\u2013314. 2015.","DOI":"10.1016\/j.jcpa.2015.08.009"}],"container-title":["Journal of Toxicologic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tox\/38\/1\/38_2024-0037\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T03:30:02Z","timestamp":1737171002000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tox\/38\/1\/38_2024-0037\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1293\/tox.2024-0037","relation":{},"ISSN":["0914-9198","1881-915X"],"issn-type":[{"value":"0914-9198","type":"print"},{"value":"1881-915X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"2024-0037"}}